[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atherosclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atherosclerosis":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,72,0,25,[9,43,79,104,134,161,187,214,247,276,299,336,371,394,414,433,452,477,503,526,546,571,596,617,642],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100627392","phase-2-a-study-to-evaluate-the-efficacy-safety-pharmacodynamics-pd-and-pharmacokinetics-pk-of-selnoflast-in-reducing-vascular-inflammation-in-participants-with-atherosclerosis-at-risk-for-major-adverse-cardiac-events-100627392",false,"NCT07448038","A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events","A Phase IIa, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Selnoflast in Reducing Vascular Inflammation in Patients With Atherosclerosis at Risk for Major Adverse Cardiac Events","RIVULET","Inclusion Criteria:\n\n* Confirmed evidence of atherosclerosis\n* Left or right carotid TBR ≥ 1.8 or aorta TBR ≥ 2.0 on centrally-assessed 18F-fluorodeoxyglucose-Positron Emission Tomography (18F-FDG-PET) scan\n* Stable treatment of atherosclerosis through the use of SOC medications or revascularization\n* QT interval corrected through use of Fridericia's formula (QTcF) of ≤ 450 milliseconds (ms) in men and ≤ 470 ms in women by a single 12-lead electrocardiogram (ECG) recording\n\nExclusion Criteria:\n\n* Individuals with Class III and IV heart failure\n* Uncontrolled cardiac arrhythmia\n* Uncontrolled hypertension\n* Suspected or known immunocompromised state\n* Planned procedure or surgery during the study and any major surgery within 90 days prior to screening Visit 1\n* History of malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer\n* Positive test results for hepatitis B (HBV) infection at screening\n* Positive hepatitis C virus (HCV) antibody test at screening\n* Positive human immunodeficiency virus (HIV) test at screening\n* Treatment with any live vaccine within 28 days prior to the first dose of study drug until the end of the study\n* Treatment with other non-live vaccines within 14 days prior to the first dose of study drug until the end of the study","ALL","18 Years","80 Years",{"count":22,"type":23},162,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adverse cardiovascular event (MACE), who are currently on standard-of-care (SOC) therapy.",[29],"Atherosclerosis","RECRUITING","2026-07-01",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":34},"2026-06-05",{"date":38,"type":23},"2028-02-28",{"name":40,"class":41},"Genentech, Inc.","INDUSTRY",15,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":18,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":4,"leadSponsor":75,"locationsCount":78},"100143838","characterization-of-patients-with-uncommon-presentations-andor-uncommon-diseases-associated-with-the-cardiovascular-system-100143838","NCT01143454","Characterization of Patients With Uncommon Presentations and\u002For Uncommon Diseases Associated With the Cardiovascular System","Cardiovascular Disease Discovery Protocol","* INCLUSION CRITERIA:\n\nEligible subjects may include anyone over 1 year of age who is affected with diseases\u002Fdisorders (index cases), or who is a relative of a person who is affected with diseases\u002Fdisorders. Relatives may include genetic carriers and non-carriers.\n\n* Healthy adult volunteers must be 18 years of age or older, and must agree to have blood or tissue samples studied, and potentially stored for future research.\n* Index cases enrolled in this protocol will have been referred with a known or suspected pathology that may be associated with cardiovascular dysfunction or risk with a suspected atypical presentation, heritable disorder, or genetic predisposition. The investigator with expertise in the presentation of the subject, along with consulting specialists, will review the medical history and may review any medical records that are available of prospective subjects and offer admission based upon the potential to help the individual, to learn from the subject, or to initiate clinical or basic research suggested by the subject s workup.\n\nEXCLUSION CRITERIA:\n\n* Persons of less than 1 year of age or greater than 100 years of age\n* Healthy volunteers unable to give informed consent or who decline to have blood and\u002For tissue studies, or who do not consent to have samples stored for future research may be excluded from this study.\n* Pregnant women\n* Persons who are not fluent in the English language will be excluded from Patient Reported Outcome Questionnaires. Such persons would be unable to properly complete questionnaires that are only valid in the English language.",true,"1 Year","100 Years",{"count":54,"type":23},5000,"OBSERVATIONAL","Background:\n\n\\- Researchers are interested in studying individuals who have known or suspected metabolic, inflammatory or genetic diseases that may put them at a high risk for heart diseases or diseases of their blood vessels. Depending on the condition being studied, both affected and nonaffected individuals may be asked to provide blood and other samples and may undergo tests to evaluate the heart, blood vessels and lung function. The testing is tailored to the individual and\u002For condition being studied. Nonaffected individuals may include relatives of affected individuals and healthy nonrelated volunteers.\n\nObjectives:\n\n\\- To study individuals who have or are at risk for cardiovascular diseases, and in some cases their unaffected relatives and healthy volunteers.\n\nEligibility:\n\n\\- Individuals between 1 and 100 years of age. Participants may be healthy volunteers, individuals with cardiovascular diseases, or unaffected relatives of individuals with cardiovascular diseases.\n\nDesign:\n\n* Participants will have some or all of the following tests, as directed by the study researchers:\n* Photography of the face and full body\n* Body measurements\n* Radiography, including chest or limb x-rays\n* Metabolic stress testing to study heart and muscle function\n* Echocardiography to study heart function\n* Magnetic resonance imaging (MRI) studies, including cardiovascular MRI, angiography, and contrast MRI, to study heart function and performance\n* Computed tomography (CT) angiogram to obtain images of the heart and lungs\n* Positron emission tomography (PET) imaging to study possible fat infiltration of the heart\n* Six-minute walk test to study heart, lung, and muscle function and performance\n* Vascular ultrasound to study blood vessel walls\n* Blood, tissue, and other specimens will be collected for research and testing, and will be taken either as part of the clinical study or during surgical procedures.\n* Follow-up studies may be performed under separate research protocols.",[58,59,60,61,29,62],"Metabolic Disease","Obesity","Li-Fraumeni Syndrome","Cardiomyopathy","Inflammatory Disease",[64,65,66,67,68,69,70],"Cardiac Disease","iPS Cells","Cardiac Risk Factors","Cardiac Disease Discovery","Natural History","Heart Disease","Heart Disease Risk","2026-06-30",{"date":31,"type":34},{"date":74,"type":34},"2010-07-21",{"name":76,"class":77},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",3,{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":86,"maxAge":52,"enrollmentInfo":87,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":4,"leadSponsor":102,"locationsCount":103},"100084203","causes-and-natural-history-of-dyslipidemias-100084203","NCT00353782","Causes and Natural History of Dyslipidemias","Disease Pathogenesis and Natural History of Lipid Disorders","* INCLUSION CRITERIA:\n* Children \\>= 2 years of age and \\>12 kg and adults\n* Dyslipidemia subjects of interest the group\n\nThe following is a representative list of the types of patient presentations with dyslipidemia and potential diagnoses eligible for this protocol:\n\n* Plasma cholesterol levels \\>200 mg\u002Fdl or \\\u003C120 mg\u002Fdl includes patients with diagnoses such as familial hypercholesterolemia, familial combined hyperlipidemia, sitosterolemia, lipoprotein lipase, hepatic lipase or apo-CII deficiency, and dysbetalipoproteinemia.\n* Plasma LDL-C levels \\>130 mg\u002Fdl or \\\u003C70 mg\u002Fdl includes patients with diagnoses such as familial hypercholesterolemia, PCSK9, apo3500, familial combined hyperlipidemia, sitosterolemia, dysbetalipoproteinemia, abetalipoproteinemia and hypobetalipoproteinemia.\n* Plasma HDL-C levels \\>70 mg\u002Fdl or \\\u003C25 mg\u002Fdl includes patients with deficiency of cholesteryl ester transfer protein, lecithin cholesterol acyltransferase, phospholipid transfer protein, lipoprotein lipase, hepatic lipase, or apo-CII, ANGPTL3, and Tangier disease.\n* Plasma triglyceride levels \\>150 mg\u002Fdl includes patients with deficiency of lipoprotein lipase, hepatic lipase or apoC-II, GPIHBP1, LMF1, dysbetalipoproteinemia, Type I, Type IV and Type V hyperlipidemia.","2 Years",{"count":88,"type":23},2000,"This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the blood in particles called lipoproteins. These particles are involved in causing blood vessel diseases that can lead to conditions like atherosclerosis (hardening of the arteries) or heart attack. Participants will undergo accepted medical tests and procedures to evaluate their condition. Most of the test results are helpful in making a diagnosis and in guiding treatment.\n\nPeople with lipid disorders are eligible for this study. Representative types of patients include those with:\n\n* Plasma cholesterol levels greater than 200 mg\u002Fdl or less than 120 mg\u002Fdl\n* Plasma LDL-C levels greater than 130 mg\u002Fdl or less than 70 mg\u002Fdl\n* Plasma HDL-C levels greater than 70 mg\u002Fdl or less than 25 mg\u002Fdl\n* Unusual cholesterol deposits or xanthomas (nodules of lipid deposits on the skin)\n\nChildren under 2 years of age are excluded from the study.\n\nParticipants will undergo some or all of the following procedures:\n\n\\- Plasma evaluation. Apolipoproteins (plasma proteins involved in metabolism of cholesterol, triglycerides, phospholipids, and proteins in the blood) and enzymes involved in lipid metabolism are measured....",[91,29],"Hypercholesterolemia",[93,94,95,96,97,68],"Triglyceride","Phospholipids","Free and Esterfied Cholesterol","Polydisperse","Lipoprotein Transport System","2026-06-27",{"date":71,"type":34},{"date":101,"type":34},"2003-10-14",{"name":76,"class":77},1,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":18,"minAge":112,"maxAge":20,"enrollmentInfo":113,"targetDuration":4,"studyType":24,"phases":115,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100641216","phase-3-a-study-to-see-if-lepodisiran-can-reduce-plaque-in-coronary-arteries-of-adults-with-elevated-lpa-who-have-had-heart-events-or-are-at-high-risk-100641216","NCT07613294","A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event","ACCLAIM-CTA","Inclusion Criteria:\n\n* Have an Lp(a) ≥175 nmol\u002FL\n* Have established cardiovascular (CV) disease or are at risk for a first CV event\n* Have angiographic evidence of coronary artery disease on screening CCTA\n* If taking lipid-lowering medications, inclusive of statins or prescription strength niacin and PCSK9 inhibitors, these should be stable for 8 weeks\n\nExclusion Criteria:\n\n* Have had a major CV event less than 60 days before measurement of the Lp(a) level used for eligibility or uncontrolled high blood pressure at screening\n* Have moderate to severe renal dysfunction\n* Have severe heart failure\n* Have a history of coronary artery bypass graft surgery (CABG)\n* Have a planned coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft, or valvular intervention\n* Have had a procedure to remove lipoproteins from the blood or received therapy specifically targeting Lp(a)\n* Are unable to safely undergo CCTA due to medication intolerance, contrast allergies, or anatomical\u002Ftechnical factors","45 Years",{"count":114,"type":23},252,[116],"PHASE3","Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a).\n\nParticipation will last about 120 weeks.",[29,119,120],"Cardiovascular Diseases","Lipoprotein(a)",[122,123],"CCTA","Coronary plaque burden","2026-06-25",{"date":126,"type":34},"2026-06-29",{"date":128,"type":34},"2026-06-02",{"date":130,"type":23},"2029-04",{"name":132,"class":41},"Eli Lilly and Company",59,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":18,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":103},"100633239","moderate-intensity-statin-plus-ezetimibe-in-ckd-and-ascvd-100633239","NCT07524101","Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD","Utilizing Lipid-lowering Therapy With Moderate-intensity Statin Plus Ezetimibe in Chronic Kidney Disease Patients With Concomitant Atherosclerotic Cardiovascular Disease: ULTRA-CKD Trial","Inclusion Criteria:\n\n1. Age 19-85 years.\n2. Chronic kidney disease stage III, IV, or V (CKD-EPI eGFR \\\u003C60 \u002F \\\u003C30 \u002F \\\u003C15 mL\u002Fmin\u002F1.73 m² or on dialysis).\n3. Established ASCVD, meeting at least one of the following:\n\n   * Prior acute coronary syndrome (myocardial infarction or unstable angina).\n   * Stable angina confirmed by imaging studies.\n   * History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting).\n   * Peripheral artery disease.\n   * Ischemic stroke or transient ischemic attack.\n\nExclusion Criteria:\n\n1. Baseline LDL cholesterol \\\u003C55 mg\u002FdL in the absence of statin therapy.\n2. Acute liver disease or persistently unexplained serum AST\u002FALT ≥2 × the upper limit of normal.\n3. Allergy or hypersensitivity to statins.\n4. Life expectancy \\\u003C1 year.\n5. Expected inability to complete at least 1 year of follow-up.\n6. Inability to read or understand the informed consent form.","19 Years","85 Years",{"count":144,"type":23},1952,[146],"NA","The ULTRA-CKD trial is a prospective, randomized, open-label, multicenter trial designed to compare the efficacy and safety of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy in patients with chronic kidney disease (CKD) and concomitant atherosclerotic cardiovascular disease (ASCVD).\n\nPatients with CKD are at very high risk for ASCVD. In this population, it is important to establish a lipid-lowering strategy that optimizes cardiovascular outcomes while ensuring long-term safety. While high-intensity statins are generally considered as initial treatment option for secondary prevention, the optimal strategy for CKD patients remains to be clinicaly defined. This study aims to evaluate whether the combination of moderate-intensity statin and ezetimibe is non-inferior to high-intensity statin monotherapy in terms of 3-year composite of major adverse cardiovascular events.",[149,29,150,91,119],"Renal Insufficiency","Dyslipidemia","2026-06-11",{"date":153,"type":34},"2026-06-16",{"date":155,"type":34},"2026-05-28",{"date":157,"type":23},"2031-01-22",{"name":159,"class":160},"Yonsei University","OTHER",{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":50,"sex":18,"minAge":19,"maxAge":52,"enrollmentInfo":168,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":170,"conditions":171,"keywords":176,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":4,"leadSponsor":185,"locationsCount":103},"100143840","study-of-the-effect-of-innate-on-the-inflammatory-response-to-endotoxin-100143840","NCT01143480","Study of the Effect of Innate on the Inflammatory Response to Endotoxin","Study of the Effect of Innate Immunity on the Inflammatory Response to Endotoxin","* INCLUSION CRITERIA:\n* Male or female 18 years of age or older\n* Participants must be able to understand and provide written informed consent to participate in the study\n* Participants must be able to travel to the CRU\n* Willing and able to fast after midnight the night prior to their study appointment.\n* Healthy participants as defined by the International Red Cross guidelines (Healthy means that an individual feels well and can perform normal activities. If the individual has a chronic condition such as diabetes or high blood pressure, healthy also means that they are being treated and the condition is under control).\n\nEXCLUSION CRITERIA:\n\n* Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 5 days prior to enrollment visit (e.g., Motrin, ibuprofen, naproxen, and Advil)\n* Use of acetaminophen (Tylenol) within 5 days prior to enrollment visit\n* Use of cholesterol lowering drugs (statins) within 30 days prior to enrollment visit (e.g., Zocor, Mevacor, Lipitor, and Crestor)\n* Use of immunosuppressants or other immune-modifying drugs \\[e.g., Rituxan, Humira, Enbrel, Cyclosporin (Neoral, Sandimmune, and SangCya), and Azathioprine (Imuran)\\], Monoclonal antibodies \\[e.g., infliximab (Remicade)\\], and corticosteroids (e.g., prednisone, prednisolone and dexamethasone)\n* Current treatment for cancer with chemotherapy or radiation\n* Confirmed or suspected immunosuppressive or immunodeficient condition\n* GI or respiratory Illness within 5 days prior to enrollment visit, including cold or allergies\n* Smoked tobacco, chewed tobacco or used electronic cigarettes within 2 weeks prior to enrollment visit (for participants who provide a urine specimen, this will be defined by urine cotinine \\>200 ng\u002FmL at visit)\n* Alcohol consumption greater than 2 standard drinks (1 standard drink contains 15 g of ethanol) per day within the last 24 hours prior to the enrollment visit\n* Body weight \\\u003C 50 kg (\\\u003C110 lbs)\n* Temperature \\> 37.6 C; blood pressure \\\u003C 90\u002F50 mm Hg or \\> 170\u002F95 mm Hg; pulse rate \\\u003C 50 or \\>100 beats\u002Fminute\n* Pregnant or suspected pregnancy\n* Chronic Kidney Disease\n\nThe PI may review medication use on a case by case basis and make a medical determination on the participant s eligibility. In these cases, the PI determination will be documented in the participant s chart.",{"count":169,"type":23},725,"Background:\n\n\\- Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by causing an inflammation. Researchers are interested in studying how the body responds to certain environmental factors, and whether the body s response can contribute to chronic illnesses or diseases such as asthma and certain types of cancers.\n\nObjectives:\n\n\\- To examine how specific genes and proteins in blood cells respond to environmental exposures.\n\nEligibility:\n\n\\- Healthy volunteers between 18 and 45 years of age.\n\nDesign:\n\n* The study will involve one visit of 45 to 60 minutes.\n* Participants will be screened with a brief physical examination and finger stick to determine if they are eligible to donate blood for the study, and will complete a questionnaire about any medications or other drugs (e.g., cigarettes) they may be taking.\n* Participants will provide a blood sample for research purposes.",[172,29,173,174,175],"Asthma","Metabolic Syndrome","Insulin Resistance","Cancer",[177,178,68,179,180],"Endotoxin","Innate Immunity","Healthy Volunteer","HV","2026-06-10",{"date":151,"type":34},{"date":184,"type":34},"2012-07-30",{"name":186,"class":77},"National Institute of Environmental Health Sciences (NIEHS)",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":24,"phases":197,"briefSummary":198,"conditions":199,"keywords":202,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":103},"100515631","petct-vs-cardiac-ct-for-detecting-coronary-atherosclerotic-disease-pet-positron-emission-tomography-ct-computed-tomography-100515631","NCT05994014","PET\u002FCT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]","PET\u002FCT vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease","PET; CT","Inclusion Criteria:\n\n* Male or female patients\n* 18 years or older\n* referred for coronary CT angiography because of suspected coronary heart disease (CHD) with stable symptoms\n\nExclusion Criteria:\n\n* The patient has a history of coronary heart disease, defined by prior myocardial infarction or prior coronary artery revascularization.\n* Pregnancy.\n* Atrial fibrillation.\n* Morbid obesity defines as a body mass index of \\>40.\n* The patient has any other clinically significant medical condition that in the opinion of the Investigator could impact the patient's ability to successfully complete the trial.",{"count":196,"type":23},33,[146],"Early detection of coronary atherosclerotic disease facilitates adequate prevention. The purpose of this study is to compare an assessment of coronary atherosclerotic disease burden by positron emission tomography \u002F computed tomography (NaF-PET\u002FCT) with those of conventional and ultra-high-resolution-CT (UHR-CT) in patients with suspected coronary artery disease. For this purpose, the investigators plan to include 33 patients with symptoms concerning for CAD who have been referred for cardiac CT testing.",[200,29,201],"Coronary Artery Disease","Coronary Atherosclerosis of Native Coronary Artery",[203,204,205],"coronary imaging","prevention","early detection",{"date":207,"type":34},"2026-06-09",{"date":209,"type":34},"2023-07-01",{"date":211,"type":23},"2027-06",{"name":213,"class":160},"Johns Hopkins University",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":18,"minAge":222,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":24,"phases":226,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":103},"100505899","using-indoor-air-filtration-to-slow-atherothrombosis-progression-in-adults-with-ischemic-heart-disease-history-100505899","NCT05867381","Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History","Slowing Atherothrombosis Progression Through Indoor Air Filtration: A Crossover Trial in Hispanic and Non-Hispanic Adults With Ischemic Heart Disease History","SAPIA","Inclusion Criteria:\n\n* Age between 65 and 84 years old;\n* Weight ≥ 110 pounds;\n* Nonsmokers for at least 1 year;\n* Have ischemic heart disease history, clinically stable for 6 months, without any deterioration in symptoms or episodes of angina based on past electronic medical records;\n* Both English and Spanish speaking participants will be included in the recruitment;\n* Live in the Los Angeles County.\n\nExclusion Criteria:\n\n* Have history of degenerative disease of the nervous system such as dementia and Alzheimer's;\n* Currently have active cancer treatments;\n* The residential house has already had HEPA filters;\n* Participants will move out from the current residential address in the next 2 years;\n* Participants will spend more than 1 month living outside the primary home;\n* Have any health conditions that prohibit collecting health and covariate data and biospecimens;\n* Participants' residential houses are not feasible for setting up air purifiers and air pollutants monitors.","65 Years","84 Years",{"count":225,"type":23},112,[146],"This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.",[229,29],"Air Pollution",[231,232,233,234,29,235,236,237],"Air pollution","Particulate matter","Air purifier","HEPA filter","Ischemic Heart Disease","Thrombosis","Cardiovascular Disease","2026-06-04",{"date":240,"type":34},"2026-06-08",{"date":242,"type":34},"2023-07-11",{"date":244,"type":23},"2028-06-30",{"name":246,"class":160},"University of Southern California",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":50,"sex":18,"minAge":19,"maxAge":52,"enrollmentInfo":254,"targetDuration":4,"studyType":24,"phases":256,"briefSummary":257,"conditions":258,"keywords":262,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":103},"100163351","new-heart-imaging-techniques-to-evaluate-possible-heart-disease-100163351","NCT01399385","New Heart Imaging Techniques to Evaluate Possible Heart Disease","Magnetic Resonance of Body, Arterial Wall, and Angiography Imaging for Non- Invasive Assessment of Arterial Distensibility, Endothelial Dysfunction and Atherosclerotic Disease Using 1.5T and High Field (3T) MRI: A Technical Development Study of Cardiac and Body Imaging","* INCLUSION:\n\n  1. Subjects with or without history of cardiovascular diseases and with various degrees of cardiovascular risk factor. Subjects with known or suspected atherosclerotic disease based on clinical findings or documented by angiography (conventional, CTA or MRA), or Doppler ultrasound. And, healthy volunteers and subjects with known or suspected diseases affecting the thoracic organs, abdominal organs, and other organs affected by metabolic diseases such as body fat and muscles. Subjects at risk for atherosclerosis including: smoking, obesity, hyperlipidemia, low levels of high density lipoproteins (\\\u003C50 mg\u002Fdl for women and \\\u003C40 mg\u002Fdl for men), hypertension, family history (early onset atherosclerosis \\\u003C55 year old in male and \\\u003C 65 year old in female who is first degree relative), and diabetes mellitus or metabolic syndrome.\n  2. Subject must be willing to participate in the protocol.\n  3. Subject age greater than 18 years old.\n  4. Subject must be able to provide informed consent.\n  5. Subject must be clinically stable and be able to come to the Clinical Center to participate in the study.\n\nEXCLUSION CRITERIA:\n\n1. Subjects with contraindication to MRI scanning. These contraindications include but are not limited to the following devices or conditions:\n\n   1. Implanted cardiac pacemaker or defibrillator\n   2. Cochlear Implants\n   3. Ocular foreign body (e.g. metal shavings)\n   4. Embedded shrapnel fragments\n   5. Central nervous system aneurysm clips\n   6. Implanted neural stimulator\n   7. Medical infusion pumps\n   8. Any implanted device that is incompatible with MRI.\n2. Unsatisfactory performance status as judged by the referring physician such that the subject could not tolerate an MRI scan. Examples of medical conditions that would not be accepted would include unstable angina and dyspnea at rest.\n3. Subjects requiring sedation for MRI studies.\n4. Subjects with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.).\n5. Pregnant or lactating women.\n6. Subjects with severe back-pain or motion disorders who will be unable to tolerate supine positioning within the MRI scanner and hold still for the duration of the examination.\n7. Subjects who are unable to undergo a CTA within 2 months of the MRA part of this study, or are unable to undergo or be scheduled for a cardiac catheterization within 2 months of the MRA.\n\nEXCLUSION CRITERIA - FOR GADOLINIUM BASED MRI STUDIES ONLY:\n\n1. History of allergic reaction to gadolinium contrast agents despite the use of premeditation with an anti-histaminic and cortisone.\n2. eGFR \\\u003C 60 ml\u002Fmin\u002F1.73m\\^2\n\nEXCLUSION CRITERIA - FOR CORONARY CTA:\n\n1. Contraindication to the use of CTA contrast agents:\n\n   1. Creatinine value \\> 1.4 mg\u002Fdl\n   2. History of multiple myeloma\n   3. Use of metformin-containing products less than 24 hrs prior to contrast administration\n   4. History of allergic reaction to CTA contrast agents despite the use of pre- medication with an anti-histaminic and cortisone.\n2. Subjects with contraindication precluding the use of beta blockers necessary to perform the coronary CTA. These include:\n\n   1. Asthma\n   2. Active bronchospasm\n   3. Moderate or severe COPD\n   4. 2nd or 3rd degree AV block\n   5. Decompensated cardiac failure\n   6. Allergy to beta blockers\n   7. Systolic blood pressure \\\u003C 100 mm Hg\n   8. Pregnancy or nursing\n\nEXCLUSION CRITERIA - FOR NITROGLYCERIN USE:\n\nSubjects reporting a history of the following conditions will be excluded:\n\n1. Severe aortic stenosis\n2. Hypertrophic cardiomyopathy\n3. Inferior myocardial infarction with right ventricular involvement\n4. Cardiac tamponade\n5. Constrictive pericarditis\n6. Severe hypotension (systolic BP \\\u003C90 mmHg)\n7. Uncorrected hypovolemia\n8. Raised intracranial pressure\n9. Glaucoma\n10. Severe anemia\n11. Concomitant use of phosphodiesterase-5 inhibitors (sildenafil-Viagra, tadalifil-Cialis, verdenafil-Levitra)\n12. History of hypersensitivity to nitroglycerin",{"count":255,"type":23},4000,[146],"Background:\n\n\\- Imaging tests, such as magnetic resonance imaging (MRI), can provide information about heart and blood vessels. The tests let doctors can see the amount of blood vessel narrowing and vessel wall thickness. This information may help diagnose and treat heart disease and other conditions that lead to heart attacks. Better MRI methods are needed to improve heart disease diagnosis, especially by avoiding the use of radiation. Researchers are testing new techniques to improve the quality of heart MRI, compared with more complex studies like catheterization or angiography.\n\nObjectives:\n\n\\- To compare heart MRI techniques with other tests used to diagnose heart disease.\n\nEligibility:\n\n\\- People at least 18 years of age who either have or may have heart disease, or are healthy volunteers.\n\nDesign:\n\n* Participants will be screened with a physical exam, medical history, and blood tests.\n* They will have an angiography to study the inside of blood vessels. This test is an x-ray study of the blood vessels. It will be done either separately or as part of a set of tests to diagnose possible heart disease.\n* Participants will have at least one and up to five MRI scans. The scans will involve different methods of studying the heart and blood vessels. Participants may also have a computed tomography scan to confirm the findings of an MRI scan.\n* No treatment will be provided as part of this protocol.",[259,59,260,261,29],"Healthy","Diabetes","Healthy Volunteers",[263,264,265,266,267,237,69,268,179,180],"Distensibility Imaging","Arteriosclerosis, Narrowing of Vessels","Endothelial Dysfunction","Hardening of the arteries","Non-Invasive Plaque Imaging","Arteriosclerosis",{"date":36,"type":34},{"date":271,"type":34},"2011-07-06",{"date":273,"type":23},"2030-11-05",{"name":275,"class":77},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":50,"sex":18,"minAge":282,"maxAge":222,"enrollmentInfo":283,"targetDuration":4,"studyType":24,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":103},"100400646","pilot-study-evaluating-the-impact-of-stress-reduction-on-atherosclerotic--heart-and-mind-study-100400646","NCT04496947","Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study","Inclusion Criteria:\n\n* • Aged between 30-65 years\n\n  * Identifies as having increased levels of stress and\u002For has a Perceived Stress Scale (PSS) score \\>5 at baseline, and is interested in participating\n\nExclusion Criteria:\n\n* Perceived Stress Scale (PSS) score \\\u003C6","30 Years",{"count":284,"type":23},30,[146],"The plot study aims to evaluate the effect of 8 weeks of stress reducing intervention on atherosclerotic plaque inflammation in adults, as quantified by positron emission tomography (PET) with fluorine-2-deoxy-D-glucose (FDG) in individuals with increased psychosocial stress.",[29,288,289],"Stress","Inflammation","2026-05-31",{"date":292,"type":34},"2026-06-03",{"date":294,"type":34},"2018-09-01",{"date":296,"type":23},"2027-12-31",{"name":298,"class":160},"Massachusetts General Hospital",{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":24,"phases":310,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":335},"100638643","phase-4-sglt2-inhibitors-on-coronary-atherosclerosis-progression-via-perivascular-adipose-tissue-in-diabetes-100638643","NCT07614230","SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes","Effects of SGLT2 Inhibitors on Coronary Atherosclerosis Progression in Diabetes Mediated by Perivascular Adipose Tissue: The SCOPE Trial","SCOPE","Inclusion Criteria:\n\n* Age between 18 and 75 years.\n* Confirmed diagnosis of type 2 diabetes mellitus with SCORE2-Diabetes risk score \\>10%.\n* Stable angina pectoris.\n* Coronary CT angiography (CCTA) demonstrating 50%-90% stenosis in at least one coronary vessel with diameter ≥2.5 mm.\n* CT-derived fractional flow reserve (CT-FFR) \\>0.8 in the target vessel.\n* Stable standard therapy for diabetes and cardiovascular disease, with no changes in SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors within the past 4 weeks.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* History of coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI) with stenting, prosthetic valve replacement, or permanent pacemaker implantation.\n* New York Heart Association (NYHA) functional class III or IV heart failure. Acute myocardial infarction within the previous 30 days.\n* Known allergy to iodinated contrast media or other contraindications to CCTA. Severe arrhythmia or coronary artery calcium (CAC) score \\>400.\n* Estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73 m². History of serious adverse reactions to SGLT2 inhibitors.\n* Pregnancy, lactation, or planned pregnancy during the study period. Severe liver dysfunction (Child-Pugh class C).\n* Any other condition that, in the investigator's opinion, makes the participant unsuitable for the trial.","78 Years",{"count":309,"type":23},144,[311],"PHASE4","This study is a multicenter, randomized controlled trial to test whether an SGLT2 inhibitor (dapagliflozin), a type of diabetes medication, can slow down or even reverse the progression of coronary atherosclerosis (plaque buildup in the coronary arteries) in patients with type 2 diabetes. The effect may be mediated by improving the function of perivascular adipose tissue. A total of 144 adults with type 2 diabetes and stable coronary artery disease will be randomly assigned to receive either dapagliflozin plus standard diabetes and cardiovascular care (intervention group) or standard care alone (control group) for 18 months. Serial coronary CT angiography and other assessments will be performed to evaluate changes in coronary plaque volume, CT-derived fractional flow reserve, perivascular fat radiomics score, and various metabolic and inflammatory markers, to determine whether SGLT2 inhibition reduces cardiovascular risk.",[314,200,29],"Type 2 Diabetes Mellitus (T2DM)",[316,317,318,319,320,321,322,323,324,325],"SGLT2 Inhibitors","Dapagliflozin","Perivascular Adipose Tissue","Coronary Atherosclerosis","Type 2 Diabetes","Plaque Progression","Coronary CT Angiography","Cardiovascular Risk","PVAT","Randomized Controlled Trial","2026-05-25",{"date":328,"type":34},"2026-05-29",{"date":330,"type":34},"2026-01-01",{"date":332,"type":23},"2028-12-31",{"name":334,"class":160},"Junjie Yang",2,{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":18,"minAge":344,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":24,"phases":347,"briefSummary":348,"conditions":349,"keywords":356,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":370},"100638937","phase-4-carotid-ultrasound-based-strategy-for-primary-prevention-of-cardiovascular-events-in-inflammatory-rheumatic-disease-prevener-100638937","NCT07611747","Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)","Randomized Clinical Trial to Assess the Efficacy and Safety of a Primary Prevention Strategy for Cardiovascular Events in Patients With Inflammatory Rheumatic Diseases Based on the Use of Carotid Ultrasound","PREVENER","Inclusion Criteria:\n\n1. Patients aged ≥50 years who have provided written informed consent.\n2. Fulfillment of classification criteria for at least one of the following inflammatory rheumatic diseases:\n\n   * Rheumatoid arthritis (RA) according to ACR\u002FEULAR 2010 criteria\n   * Psoriatic arthritis (PsA) according to CASPAR criteria\n   * Axial spondyloarthritis (AxSpA) according to ASAS criteria\n   * Systemic lupus erythematosus (SLE) according to ACR\u002FEULAR 2019 criteria\n3. Low-to-moderate cardiovascular risk according to SCORE2\u002FOP classification.\n\nExclusion Criteria:\n\n1. Presence of previous cardiovascular events, type 2 diabetes mellitus, familial hypercholesterolemia, or chronic kidney disease resulting in classification as high or very high cardiovascular risk.\n2. Prior carotid ultrasound examination with subsequent therapeutic intervention derived from its results, either in the context of a research study or routine clinical practice.\n3. Contraindications to lipid-lowering therapy, including recent history of alcoholism, active liver disease, or unexplained and persistent elevation of serum transaminases exceeding three times the upper limit of normal (applicable to statins and ezetimibe).","50 Years",{"count":346,"type":23},1944,[311],"PREVENER is a randomized, open-label, multicenter, phase IV clinical trial designed to evaluate the efficacy and safety of a carotid ultrasound-based strategy for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases (IRD).\n\nPatients with IRD, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), and systemic lupus erythematosus (SLE), have a 50% higher risk of cardiovascular (CV) events compared to the general population. However, conventional CV risk scores (SCORE2\u002FOP) systematically underestimate this risk, leaving many high-risk patients without appropriate preventive treatment.\n\nPatients aged ≥50 years with IRD and low-to-moderate CV risk according to SCORE2\u002FOP will be randomized 1:1 to either an experimental group (carotid ultrasound to detect subclinical atherosclerosis) or a control group (standard care according to ESC 2021 guidelines). Patients in the experimental group with carotid plaques will be reclassified as very high CV risk and treated with high-intensity statins (LDL target \\\u003C55 mg\u002FdL). The primary endpoint is the incidence of major adverse cardiovascular events (MACE) over 48 months of follow-up.",[350,351,352,353,354,29,355],"Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)","Axial Spondy","Systemic Lupus Erythematosus (SLE)","Caridovascular Disease","Carotid Artery Diseases",[357,358,359,360,361],"Carotid ultrasound","Carotid plaques","Subclinical atherosclerosis","Cardiovascular prevention","Inflammatory rheumatic diseases","2026-05-20",{"date":155,"type":34},{"date":365,"type":34},"2026-04-22",{"date":367,"type":23},"2031-12",{"name":369,"class":160},"Instituto de Investigación Marqués de Valdecilla",17,{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":50,"sex":18,"minAge":112,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":24,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":103},"100457351","high-protein-diet-and-atherosclerosis-100457351","NCT05235464","High Protein Diet and Atherosclerosis","Dissecting the Impact of Dietary Protein on Macrophage mTOR Signaling and Atherosclerosis","HPA","Inclusion Criteria:\n\n* \\>=45 and \\\u003C=75 years of age\n* body mass index \\>=25.0 and \\\u003C40.0 kg\u002Fm2\n\nExclusion Criteria:\n\n* \\\u003C45 and \\>75 years of age\n* body mass index \\\u003C25.0 or \\>39.9 kg\u002Fm2\n* plasma triglyceride \\\u003C125 mg\u002Fdl\n* history of or current significant organ system dysfunction\n* allergies or intolerances to meal ingredients\n* use of medications or dietary supplements that could confound the study outcomes\n* engaged in regular structured exercise \\>150 min per week\n* alcohol use disorder\n* premenopausal women\n* persons who smoke\n* prisoners\n* inability to grant voluntary informed consent","75 Years",{"count":381,"type":23},24,[146],"Atherosclerosis is the underlying cause of the majority of cardiovascular diseases, including myocardial infarction and strokes, and results in tremendous morbidity and mortality. A Western-type diet is a major risk factor for atherosclerosis because of the high saturated fat, cholesterol, and refined carbohydrate contents. Dietary strategies to reduce cardiovascular disease burden therefore focus on restriction of saturated fat, cholesterol, and refined carbohydrates whereas \"lean\" protein intake is recommended and has become popular. However, results from studies conducted in animal models suggest high dietary protein intake is also atherogenic. The investigators' extensive preliminary data in animal models show that dietary protein increases atherosclerotic plaque formation and size and promotes necrotic core formation, a characteristic of rupture-prone plaques. The goal of the current proposal is to provide deeper insights into the relationship between protein intake and the pathogenesis of atherosclerosis by studying the mechanisms involved in protein-mediated atherogenesis and formation of necrotic plaques. The overarching hypothesis is that high protein intake drives atherosclerosis via leucine-mediated mTORC1 signaling in macrophages, which inhibits macrophage mitophagy and aggrephagy and stimulates macrophage proliferation. Furthermore, the investigators hypothesize that proteins from animal sources are more atherogenic than proteins from plant sources, because animal proteins contain more leucine than plant proteins. The investigators will test these hypotheses by using a sophisticated array of experimental strategies, including assays in primary macrophages and human monocyte-derived macrophages and genetically engineered mouse models. In addition, they will begin to translate the results obtained in vitro and in animals to people, and explore approaches to pharmacologically target the pro-atherogenic pathways as novel cardiovascular therapeutics. This proposal represents a paradigm shift in how a Western-type diet affects vascular health which has important implications since many adults in Western societies consume excess protein and dietary protein is heavily marketed for its presumed beneficial health effects.",[29],"2026-05-05",{"date":387,"type":34},"2026-05-11",{"date":389,"type":34},"2023-03-13",{"date":391,"type":23},"2028-03-31",{"name":393,"class":160},"University of Missouri-Columbia",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":18,"minAge":141,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":24,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":103},"100547036","phase-4-clopidogrel-versus-cilostazol-on-vessels-100547036","NCT06402747","Clopidogrel Versus Cilostazol on Vessels","Comparing Clopidogrel and Cilostazol in Type 2 Diabetes Patients With Carotid Atherosclerosis","Inclusion Criteria:\n\n* Adults with diabetes aged 19 and older\n* Individuals with a carotid ultrasound cIMT (carotid intima-media thickness) of 1.0mm or more\n* Those who have not changed their combination therapy medications (including oral hypoglycemics, antihypertensives, and lipid-lowering drugs) in the last three months\n* Individuals with an HbA1c level of 10% or less\n* Those who have voluntarily signed the written consent form and agreed to participate in the study\n\nExclusion Criteria:\n\n* Individuals currently using antithrombotic or anticoagulant medications other than aspirin\n* Individuals with bleeding or conditions that may increase the risk of bleeding, such as:\n\n  * Hemophilia, capillary fragility, intracranial hemorrhage, upper gastrointestinal bleeding, urinary bleeding, hemoptysis, vitreous hemorrhage, etc\n  * Active peptic ulcer, hemorrhagic stroke within the last 6 months, surgical operations within the last 3 months, proliferative diabetic retinopathy, uncontrolled hypertension\n* Patients who have had cerebrovascular or cardiovascular complications within the past 6 months (including stroke, transient ischemic attacks, myocardial infarction, unstable angina, coronary artery bypass graft, or percutaneous coronary intervention)\n* Patients with severe renal or hepatic diseases\n* Patients with congestive heart failure\n* Individuals with a history of hypersensitivity to the drug or its components\n* Pregnant women or women who may be pregnant\n* Women who are breastfeeding or plan to breastfeed during the study",{"count":402,"type":23},120,[311],"Diabetes is an increasing cause of atherosclerotic and cardiovascular illnesses in South Korea. The clinical application of ultrasound for measuring carotid intima-media thickness, which helps in early detection and surveillance of atherosclerosis, is advancing. Due to lifestyle changes and an aging population, Koreans, especially diabetics, are developing more vascular diseases and are at higher risk for peripheral vascular disorders. Diabetics with lower limb peripheral artery disease require effective therapy to avoid major complications and a reduced quality of life. Although licensed for symptom control, Clopidogrel and Cilostazol have not yet been established for primary prevention of cardiovascular risks. These medications will be evaluated for their potential as primary preventive agents against cardiovascular disease in type 2 diabetes patients. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and to evaluate their influence on hemorheological changes in individuals with Type 2 diabetes. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and evaluating their influence on alterations in blood flow among individuals with Type 2 diabetes.",[320,29],"2026-05-02",{"date":385,"type":34},{"date":409,"type":34},"2024-04-16",{"date":411,"type":23},"2027-01-31",{"name":413,"class":160},"Seoul National University Bundang Hospital",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":18,"minAge":421,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":24,"phases":424,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":432,"locationsCount":103},"100467335","phase-4-choline-fenofibrate-and-carotid-atherosclerosis-in-patients-with-type-2-diabetes-and-combined-dyslipidemia-100467335","NCT05365425","Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","Effect of Choline Fenofibrate on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia","Inclusion Criteria:\n\n* Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit\n* Male or female of 20 years or over\n* Mixed dyslipidemia: triglyceride 200\\~499 mg\u002FdL, HDL-cholesterol male ≤45 mg\u002FdL or female ≤50 mg\u002FdL\n* Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm\n* Creatinine ≤1.8 mg\u002FdL\n\nExclusion Criteria:\n\n* Dyslipidemia which requires other therapy: triglyceride ≥500 mg\u002FdL or LDL-cholesterol ≥190 mg\u002FdL\n* Uncontrolled hypertension\n* Severe renal dysfunction\n* GOT\u002FGPT \\>120\u002F120 or chronic liver disease\n* Pregnant or childbearing woman who does not have enough contraception\n* Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months\n* Other antiplatlet medication such as cilostazol, clopidogrel (except aspirin)","20 Years",{"count":423,"type":23},56,[311],"This is a randomized controlled study to assess the effect of choline fenofibrate compared with policosanol in Korean T2DM patients with asymptomatic atherosclerosis.",[150,29,427],"Diabetes Mellitus, Type 2",{"date":385,"type":34},{"date":430,"type":34},"2023-06-01",{"date":296,"type":23},{"name":413,"class":160},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":18,"minAge":421,"maxAge":20,"enrollmentInfo":440,"targetDuration":4,"studyType":24,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":103},"100467336","phase-4-atmeg-atorvastatin-and-omega-3-combination-and-carotid-atherosclerosis-in-patients-with-type-2-diabetes-and-combined-dyslipidemia-100467336","NCT05365438","Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","Effect of Atorvastatin and Omega 3 Combination Therapy on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia","Inclusion Criteria:\n\n* Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit\n* Male or female of 20 years or over\n* Mixed dyslipidemia under moderate-intensity statin: triglyceride ≥200 mg\u002FdL, HDL-cholesterol ≤50 mg\u002FdL, LDL-cholesterol ≥100 mg\u002FdL\n\n  * moderate-intensity statin: atorvastatin 10-20mg, rosuvastatin 5mg, simvastatin 20-40mg, pravastatin 40-80mg, lovastatin 40mg, fluvastatin XL 80mg, fluvastatin 40mg bid, pitavastatin 2-4mg\n* Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm\n* Asymptomatic patients without history of angina, myocardial infarction, or cerebral infarction\n* Creatinine ≤1.8 mg\u002FdL\n\nExclusion Criteria:\n\n* Dyslipidemia which requires other therapy: triglyceride ≥500 mg\u002FdL or LDL-cholesterol ≥190 mg\u002FdL\n* Uncontrolled hypertension: SBP \\>180 mmHg or DBP \\>110 mmHg\n* Severe renal dysfunction: eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2\n* AST\u002FALT \\>120\u002F120 or chronic liver disease\n* Pregnant or childbearing woman who does not have enough contraception\n* Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months\n* Usage of dyslipidemia therapy other than statin",{"count":441,"type":23},105,[311],"This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.",[445,29,427],"Dyslipidemias",{"date":385,"type":34},{"date":448,"type":34},"2022-10-01",{"date":450,"type":23},"2026-12-31",{"name":413,"class":160},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":24,"phases":462,"briefSummary":463,"conditions":464,"keywords":465,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":103},"100499007","improving-adherence-to-statin-therapy-through-a-medication-management-application-100499007","NCT05777655","Improving Adherence to Statin Therapy Through a Medication Management Application","Improving Adherence to Statin Therapy Through a Medication Management Application (STAPP)","STAPP","Inclusion Criteria:\n\n* Age \\>18 years\n* Atherosclerosis (neurovascular, cardiac or peripheral) with an indication to start a high intensity statin-therapy (equivalent to 40mg of atorvastatin or 20mg of rosuvastatin; start of statin therapy +\u002F- 10 days of enrolment)\n* Statin naivety\n* LDL-C \\>100 mg\u002Fdl. No older than 21 days\n\nExclusion Criteria:\n\n* Inability to take medication independently or to use the mediteo m+ app independently (e.g. people in need of care, people with dementia)\n* Patient has no own smartphone (no device provided for this study)\n* Prior drug therapy to lower LDL-C within the last 30 days\n* Active cancer (defined as a diagnosis of cancer within 6 months before enrolment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer) or other severe concomitant disease with a life expectancy of \\\u003C6 months\n* Use of a digital therapy management application (including mediteo or mediteo m+) within the last month\n* Participation in another interventional trial\n* Pregnancy\n* Inability or unwillingness to provide informed consent",{"count":461,"type":23},250,[146],"Interventional study to compare standard of care vs standard of care plus the use of a medication therapy management smartphone app (mediteo m+, Mediteo GmbH, Heidelberg) in patients with atherosclerotic cardiovascular disease and indication to start high intensity statin therapy.",[29],[466,467],"Smartphone Application","Medication Therapy Management","2026-04-28",{"date":470,"type":34},"2026-05-04",{"date":472,"type":34},"2023-02-17",{"date":474,"type":23},"2028-11-28",{"name":476,"class":160},"University Hospital, Essen",{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":487,"conditions":488,"keywords":491,"overallStatus":494,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":501,"locationsCount":4},"100635865","carotid-intima-media-thickness-in-dialysis-patients-and-traditional-risk-factors-100635865","NCT07558239","Carotid Intima-media Thickness in Dialysis Patients and Traditional Risk Factors","Association of Traditional Cardiovascular and Dialysis-Specific Risk Factors With Carotid Intima-Media Thickness in Hemodialysis Patients: A Cross-Sectional Study\"","Inclusion Criteria:\n\n* 1\\. Age 18 or older. 2. Patients with sepsis without AKI at the time of admission.\n\nExclusion Criteria:\n\n* o Active malignancy\n\n  * Acute infections\n  * Recent cardiovascular events (\\\u003C3 months)\n  * Poor echocardiographic window for CIMT measurement","70 Years",{"count":486,"type":23},100,"* Cardiovascular disease (CVD) is the leading cause of mortality in hemodialysis (HD) patients.\n* Carotid intima-media thickness (CIMT) is a validated surrogate marker for atherosclerosis.\n* Both traditional cardiovascular risk factors (hypertension, diabetes, dyslipidemia) and dialysis-specific factors (mineral metabolism disorders, dialysis duration) contribute to vascular damage.",[489,490,29],"Dialysis Patients","Hypertension",[492,493],"Renal dialysis","Carotid intima- media thickness","NOT_YET_RECRUITING","2026-04-23",{"date":497,"type":34},"2026-04-30",{"date":499,"type":23},"2026-04-24",{"date":31,"type":23},{"name":502,"class":160},"Minia University",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":525},"100591197","evaluation-of-a-diagnostic-software-for-coronary-artery-disease-using-retrospective-ccta-data-codex-1-study-100591197","NCT06977295","Evaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study)","CODEX1 TRIAL: Complete One-Stop-Shop Diagnosis Of Coronary Artery Disease On Computed Coronary Tomography Angiography: From the COMBINE-CT Study","CODEX1","Inclusion Criteria:\n\n* Age 18 years or older\n* Underwent coronary computed tomography angiography (CCTA) for the diagnosis or assessment of coronary artery disease (CAD) between 2019 and 2024\n* Availability of comparator diagnostic data within 1 month before or after the CCTA, such as: Invasive coronary angiography (ICA), Stress MRI, Alternative CCTA analysis software, Documented clinical events\n\nExclusion Criteria:\n\n\\- Insufficient image quality to determine coronary stenosis or assess CAD parameters in routine clinical use",{"count":512,"type":23},1000,"The CODEX-1 study is a multicenter retrospective observational study designed to assess the diagnostic performance of a novel software application for coronary artery disease (CAD) evaluation. The application integrates automated stenosis detection, CT-derived fractional flow reserve (CT-FFR), and plaque quantification, all performed on-site. A total of 1,000 patients who previously underwent coronary computed tomography angiography (CCTA) and diagnostic invasive coronary angiography (ICA) and\u002For other non-invasive imaging will be included. The study compares the diagnostic outputs of the software to current clinical practice and expert adjudication, focusing on CAD-RADS categorization, prediction of the need for percutaneous coronary intervention (PCI), and reduction in unnecessary ICA procedures.",[200,29,515],"Myocardial Ischemia","2026-04-20",{"date":518,"type":34},"2026-04-21",{"date":520,"type":34},"2025-07-14",{"date":522,"type":23},"2027-04-30",{"name":524,"class":160},"Instituto de Investigación Biomédica de Salamanca",4,{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":18,"minAge":533,"maxAge":19,"enrollmentInfo":534,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":536,"conditions":537,"keywords":4,"overallStatus":494,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":4},"100634878","subclinical-atherosclerosis-in-juvenile-systemic-lupus-erythematosus-100634878","NCT07545408","Subclinical Atherosclerosis in Juvenile Systemic Lupus Erythematosus","Subclinical Atherosclerosis in Juvenile Systemic Lupus Erythematosus: Evaluation by Carotid Intima-Media Thickness and Associated Cardiovascular Risk Factors","Inclusion Criteria:\n\n\\- Children and adolescents aged under 18 years diagnosed with JSLE according to the Systemic Lupus International Collaborating Clinics ( SLICC 2012 Criteria ).\n\nDisease duration of at least 6 months.\n\nUnder regular follow-up at the study institution.\n\nExclusion Criteria:\n\n* Patients with other autoimmune or connective tissue overlap diseases (e.g., mixed connective tissue disease, juvenile dermatomyositis).\n\nPatients with congenital heart disease or known structural cardiovascular abnormalities.\n\nPatients with chronic kidney disease stage 4 or 5.\n\nPatients currently receiving lipid-lowering therapy prior to enrolment","0 Years",{"count":535,"type":23},70,"The aim of this study is to evaluate subclinical atherosclerosis in children and adolescents with juvenile SLE by measuring carotid intima-media thickness (CIMT), and to determine its associations with traditional cardiovascular risk factors (dyslipidemia, hypertension, obesity) and non-traditional disease-related risk factors (disease activity, lupus nephritis, corticosteroid dose, disease duration).",[29],"2026-04-16",{"date":365,"type":34},{"date":541,"type":23},"2026-06-01",{"date":543,"type":23},"2027-08-01",{"name":545,"class":160},"Assiut University",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":379,"enrollmentInfo":553,"targetDuration":4,"studyType":24,"phases":555,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":335},"100576679","early-phase-1-a-clinical-study-of-imc-001-for-injection-in-improving-atherosclerotic-plaque-stability-in-patients-with-acute-coronary-syndrome-100576679","NCT06788431","A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.","A Two-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Investigator-Initiated Trial (IIT) Evaluating the Safety and Preliminary Efficacy of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.","Inclusion Criteria:\n\n1. Fully comprehend the purpose, characteristics, methodology, and potential adverse reactions of this study; voluntarily participate in the research and sign an informed consent form prior to any related assessments;\n2. Male or female subjects aged ≥18 years and ≤75 years;\n3. Clinically diagnosed with acute coronary syndrome (ACS) (including acute myocardial infarction or unstable angina) and meeting the following criteria:\n\n   ① Patients with ≥30% and \\\u003C70% stenosis in the target vessel as demonstrated by coronary angiography or coronary CTA;\n\n   ② At least one plaque exhibiting detectable low attenuation (coronary CTA -30 HU to 30 HU), with calcified volume constituting \\\u003C50% of total plaque volume;\n\n   ③ High-sensitivity C-reactive protein (hsCRP) ≥ 1.0 mg\u002FL;\n4. Patients must receive guideline-directed standard treatment for coronary artery disease;\n5. Women of childbearing potential or men (unless their partner is infertile) must agree to use medically approved contraception from screening until 6 months after the last dose; Male subjects must not donate sperm, and female subjects must not donate eggs for at least 6 months after signing the informed consent form and until 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Participation in any drug or medical device clinical trial within one month prior to screening.\n2. Previous treatment with coronary artery bypass grafting (CABG), left ventricular assist device (LVAD) implantation, heart transplantation, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or any planned procedure for these treatments during the study period.\n3. New York Heart Association (NYHA) functional class III or IV, or a known recent left ventricular ejection fraction (LVEF) \\\u003C 40% (as determined by left ventricular angiography, radionuclide ventriculography, or echocardiography).\n4. Uncontrolled arrhythmia within 3 months prior to screening, defined as recurrent, symptomatic, and refractory to medical therapy, such as ventricular tachycardia, atrial fibrillation with rapid ventricular rate and paroxysmal supraventricular tachycardia, or a family history of long QT syndrome.\n5. Evidence of active or suspected malignancy within 3 years prior to screening (excluding only carcinoma in situ or basal\u002Fsquamous cell skin cancer treated with curative therapy); life expectancy less than 1 year.\n6. Any major surgery within 3 months prior to screening or planned major surgery during the study period;\n7. Presence or suspected ongoing severe infection within 8 weeks prior to first dosing (defined as requiring hospitalisation or intravenous anti-infective therapy), chronic or recurrent bacterial, fungal, or viral infections requiring medical intervention, including syphilis, human immunodeficiency virus (HIV) infection, active hepatitis B or C infection history;\n8. Presence of severe hepatic dysfunction, defined as: any alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level \\> 3 times the upper limit of normal (ULN) at final screening assessment.\n9. Moderate to severe renal impairment, defined as: estimated glomerular filtration rate (eGFR) \\\u003C 45 mL\u002Fmin\u002F1.73 m²at screening (calculated using the 2021 CKD-EPI formula; see Appendix 4), or serum creatinine \\> 1.5 × ULN.\n10. Presence of any type of autoimmune disease; current or planned systemic anti-inflammatory therapy, such as immunomodulatory agents and chemotherapeutic agents.\n11. Individuals who have donated blood or experienced blood loss\n\n    ≥400 mL within 3 months prior to dosing, have a history of severe spontaneous bleeding, or have received blood transfusions or blood products. Abnormal laboratory parameters within 7 days without transfusion, including but not limited to: white blood cell count below the lower limit of normal, neutrophil count \\\u003C1.5×109\u002FL, haemoglobin \\\u003C100 g\u002FL, platelet count ≤100×109 \u002FL, total bilirubin \\>1.5×ULN, International Normalised Ratio (INR) \\>2×ULN, or activated partial thromboplastin time (APTT) \\>2×ULN.\n12. Known prior allergy to macromolecular protein preparations\u002Fmonoclonal antibodies, known allergy to the investigational medicinal product or its excipients or similar drugs, prior treatment with IMC-001.\n13. Existence of contraindications for CCTA examination and history of iodine contrast agent allergy, etc.\n14. Screening CCTA reveals moderate to severe calcification (coronary artery calcium score \\[Agatston score\\] ≥ 300) or tortuosity in target vessels, judged by the investigator to compromise study assessment.\n15. Receipt of any type of vaccination within one month prior to screening, or planned vaccination during the study treatment period.\n16. History of substance abuse (including illicit drug use) and\u002For alcohol abuse within 6 months prior to screening; subjects with alcohol abuse defined as consuming 14 units of alcohol weekly: 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine.\n17. Pregnant or lactating women; those with a positive pregnancy test during the screening period.\n18. Any other disease or condition deemed by the investigator to make the subject unsuitable for participation in this study, in addition to those listed above.",{"count":554,"type":23},18,[556],"EARLY_PHASE1","A two-center, randomized, double-blind, placebo-controlled, dose-escalation IIT clinical study evaluating the safety and preliminary efficacy of injectable IMC-001 in improving atherosclerotic plaque stability in patients with acute coronary syndrome. The plan is to conduct 2 dose groups, with 9 subjects enrolled in each group, including 6 in the treatment group and 3 in the control group. The treatment group will receive IMC-001 along with optimal drug therapy, with a total of 12 subjects included, while the control group will receive a placebo along with optimal drug therapy, with a total of 6 subjects included.",[29],[560,561],"Acute coronary syndrome","atherosclerosis","2026-04-12",{"date":564,"type":34},"2026-04-15",{"date":566,"type":34},"2025-03-10",{"date":568,"type":23},"2026-10-30",{"name":570,"class":160},"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.",{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":579,"targetDuration":4,"studyType":24,"phases":581,"briefSummary":582,"conditions":583,"keywords":584,"overallStatus":494,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":591,"leadSponsor":593,"locationsCount":595},"100633001","phase-2-a-phase-2b-clinical-trial-of-yn001-in-adults-with-coronary-atherosclerosis-100633001","NCT07521007","A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis","A Randomized, Multicenter, Double-Blind, Parallel, Placebo-controlled Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of YN001 in Adults With Coronary Atherosclerosis","PURIFY-TIMI 81","Inclusion Criteria:\n\n1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.\n2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).\n3. Participants must satisfy either of the following criteria:\n\n1\\) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening\u002Fbaseline, as evidenced by:\n\n1. A history of Type 2 diabetes requiring treatment with medication,\n2. Aged \\> 55 years (women) or \\> 50 years (men),\n3. 2 or more of the following atherosclerosis risk factors:\n\n   * Current cigarette smoker\n   * Hypertension\n   * Estimated glomerular filtration rate (eGFR) 45 to 60 ml\u002Fmin\u002F1.73m2\n\n     4\\. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.\n\n     5\\. Female participants must be non-pregnant and non-lactating\n\n     6\\. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.\n\nExclusion Criteria:\n\n1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.\n2. Previously received YN001.\n3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period\n4. Contraindication for CCTA\n5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.\n6. Acute MI that occurred within 4 weeks prior to randomization.\n7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.\n8. Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.\n9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.\n10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.\n11. New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was \\\u003C40%.\n12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.\n13. History of myopathy or myositis, or susceptibility to myopathy\u002Frhabdomyolysis (e.g., family history of hereditary myopathy, etc.).\n14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.\n15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal\u002Frectal bleeding within 6 months prior to randomization.\n16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.\n17. Presenting with history of malignancy (except in participants who have been disease-free \\>5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).\n18. Presence of any type of autoimmune disease.\n19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.\n20. Life expectancy is less than 1 year.\n21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.\n22. Triglycerides ≥ 400 mg\u002FdL (4.5 mmol\u002FL) at final screening.\n23. LDL-C \\> 100 mg\u002FdL (2.6 mmol\u002FL) at final screening.\n24. Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), \\> 3 times upper limit of normal (ULN), or total bilirubin \\> 2 times ULN at final screening.\n25. Presence of renal dysfunction, defined by eGFR \\\u003C 45 ml\u002Fmin\u002F1.73m2.\n26. Untreated or inadequately treated hypothyroidism.\n27. Poorly controlled Type 2 diabetes mellitus.\n28. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).\n29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.",{"count":580,"type":23},456,[26],"This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.",[29,200],[585,586],"Plaque regression","Plaque stabilization","2026-04-02",{"date":589,"type":34},"2026-04-09",{"date":497,"type":23},{"date":592,"type":23},"2029-03-31",{"name":594,"class":41},"Beijing Inno Medicine Co., Ltd.",13,{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":604,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":606,"conditions":607,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":103},"100533791","t-mem-gene-in-atherosclerosis-100533791","NCT06230406","T-Mem GEne in Atherosclerosis","Role of T-Mem GEne in the Molecular Pathogenesis of Atherosclerosis","GEMMA","Inclusion Criteria:\n\n* adult patients (age \\> 18 years)\n* consent to participate in the study,\n* patients coming to the Vascular Surgery Unit I of the IRCCS Policlinico San Donato for a vascular pathology of the arterial or venous district worthy of surgical treatment.\n\nExclusion Criteria:\n\n* minor patients,\n* patients who have not given their consent to participate in the study,\n* patients who have vascular pathologies of the arterial or venous district not susceptible to surgical intervention.",{"count":605,"type":23},12,"Atherosclerosis is the main cause of cardiovascular diseases and is characterized by the progressive accumulation of lipids and inflammatory cells such as macrophages and lymphocytes within the vessel wall of large and medium-sized arteries, forming the so-called \"atherosclerotic plaques\". The formation process of these lesions is different depending on the age, genetics and physiological state of the individual affected. Furthermore, behavioral factors and the lifestyle of each individual play a key role, which can lead to the presence of a series of pro-atherosclerotic pathologies and risk factors, such as in particular systemic arterial hypertension, dyslipidemia, hyperglycemia and cigarette smoking. However, the precise molecular mechanisms underlying this pathogenetic process are still under investigation.\n\nThe results of a study conducted in the past in collaboration between the U.O. have recently been published. of Vascular Surgery and the laboratory of Dr. I. Zucchi of the Institute of Biomedical Technologies of the CNR of Milan Segrate (Protocol GEMMA NUOVA, 16\u002Fint\u002F2016), which describes that the overexpression of a newly identified gene (TMEM230) it may have a role in the formation of atherosclerotic vascular disorders, but it is still unclear how the expression of this gene is modulated in vivo.\n\nKnowledge of these factors would increase the knowledge of the molecular mechanisms underlying atherosclerosis and could represent a possible target for prevention and targeted pharmacological treatment, with consequent potential reduction in disability or mortality from cardiovascular diseases.",[29],"2026-04-01",{"date":610,"type":34},"2026-04-07",{"date":612,"type":34},"2023-09-28",{"date":614,"type":23},"2026-12",{"name":616,"class":160},"IRCCS Policlinico S. Donato",{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":50,"sex":18,"minAge":624,"maxAge":484,"enrollmentInfo":625,"targetDuration":4,"studyType":24,"phases":627,"briefSummary":628,"conditions":629,"keywords":630,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":640,"locationsCount":103},"100560642","cardiac-rehabilitation-and-coronary-artery-disease-100560642","NCT06579807","Cardiac Rehabilitation and Coronary Artery Disease","Effect of a Cardiovascular Rehabilitation Program on Atherosclerosis, Endothelial Function and Inflammation in Patients With Coronary Artery Disease","Inclusion Criteria:\n\n* Eligible CAD patients will be those aged 40 to 70 years, of both sexes, entering the cardiac rehabilitation program at HUPE. CAD will be defined as any acute coronary syndrome, including myocardial infarction with and without ST-segment elevation, and unstable angina (all defined by characteristic histories, electrocardiographic abnormalities, and cardiac enzyme abnormalities), or obstructive CAD diagnosed via coronary angiography (defined as ≥ 50% stenosis of any epicardial coronary artery) in patients with stable angina.\n* Healthy controls: adults aged 40 to 70 years, of both sexes, without CAD evidence.\n\nExclusion Criteria:\n\n* diagnosis of heart failure, pulmonary disease, Chagas disease, or tuberculosis\n* regular physical exercise practice (≥ 3 days\u002Fweek for 30 min) over the past 6 months\n* malnutrition (body mass index \\[BMI\\] \\\u003C 18.5 kg\u002Fm²)\n* smoking\n* obesity (BMI ≥ 30 kg\u002Fm²)","40 Years",{"count":626,"type":23},50,[146],"Patients with coronary artery disease (CAD) aged 40-70 years will undergo exercise training (thrice weekly for 12 weeks). A reference group composed of healthy individuals will be included. Evaluations will be conducted at baseline and after the intervention period during two visits. During the first visit, carotid artery thickness will be assessed via ultrasound before and after a cardiopulmonary exercise testing. The second visit will include the evaluation of endothelial function using venous occlusion plethysmography. After this, participants will engage in 30 minutes of moderate-intensity aerobic exercise, and blood samples will be collected pre- and post-exercise. Circulating levels of kynurenine pathway (KP) metabolites (Tryptophan, kynurenine, kynurenic acid, and quinolinic acid), pro-inflammatory cytokines, cell adhesion molecules, and lipid profiles will be measured via Enzyme-Linked Immunosorbent Assay (ELISA), multiplex essays, and biochemical analysis; respectively.",[200,29],[631,632,289,633],"Cardiac rehabilitation","Physical training","Intercellular adhesion molecules","2026-03-23",{"date":636,"type":34},"2026-03-27",{"date":638,"type":34},"2024-10-01",{"date":450,"type":23},{"name":641,"class":160},"Instituto Nacional de Cardiologia de Laranjeiras",{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":18,"minAge":648,"maxAge":649,"enrollmentInfo":650,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":652,"conditions":653,"keywords":654,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":103},"100568041","natural-history-of-uncommon-dyslipidemias-rare-lipid-disorders-and-unusual-atherosclerotic-conditions-100568041","NCT06676046","Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions","* INCLUSION CRITERIA:\n\nAffected Participants\n\n* Male and female participants age \\>= 10 years.\n* Subjects with confirmed or suspected rare disorder that causes lipid\u002Flipoprotein abnormalities (dyslipidemia) or abnormal documented or referred atherosclerosis patterns.\n* Only affected individuals (not healthy volunteers and for self-referred subjects independent of lipid and lipoprotein marker values.); subjects with laboratory or clinical presentation that in the opinion of the Principal Investigator, would alter the determination of normal\n\nparameters for assays and screening tools development.\n\n-Ability of the subject or Legally Authorized Representative (LAR) to understand and willingness to sign a written informed consent document.\n\nHealthy Volunteers\n\n* Participants must be healthy, with no known history of lipid disorders or related medical conditions.\n* Participants must not be pregnant.\n\nEXCLUSION CRITERIA:\n\n* Patients with disorders that cause common secondary\u002Flipoprotein alterations.\n* Patients with any other findings that, in the opinion of the Principal Investigator, would preclude them from participating in the study.","10 Years","90 Years",{"count":651,"type":23},1500,"Background:\n\nThe right amount of fats in the blood (cholesterol and triglycerides) are a key part of a healthy organism. Too much or too little of these fats may manifest as diseases (dyslipidemia). There are many causes for these abnormalities, but some are genetically determined and we would like to better understand the progression of these conditions over time.\n\nObjective:\n\nThis natural history study aims to learn more about dyslipidemias; how they change over time; and how they respond to therapy. We also want to develop new diagnosis methods for these conditions. With the knowledge we will acquire we hope to provide new insights, new approaches and improve the overall health of these patients.\n\nEligibility:\n\nIndividuals aged 10 years and older, residing both within and outside the United States, who have or are suspected of having a disorder that causes changes in the levels of fats in their blood (genetic dyslipidemias).\n\nDesign:\n\nParticipants residing within and outside the United States will be screened. Their medical records may be reviewed. They may talk to researchers about their medical history by phone, telehealth, or in person.\n\nAll study visits are optional. Participants may visit the NIH up to 15 times per year, if needed.\n\nEach visit may include a physical exam and blood tests. Participants may also have an electrocardiogram (EKG). The EKG measures the electrical activity when the heart beats.\n\nIn some cases, participants may remain in the study for up to 20 years.",[150,29],[655,656,657,658,29,659],"Uncommon Dyslipidemias","Rare Lipid Disorders","Unusual Atherosclerotic Conditions","Lipoproteins","TRIGLYCERIDES","2026-03-20",{"date":634,"type":34},{"date":663,"type":34},"2025-01-15",{"date":665,"type":23},"2044-11-24",{"name":76,"class":77}]